DOH, FDA allow use of CoronaVac on senior citizens | Inquirer News

DOH, FDA allow use of CoronaVac on senior citizens

By: - Reporter / @DYGalvezINQ
/ 07:04 PM April 07, 2021

MANILA, Philippines — The Department of Health (DOH) and the Food and Drug Administration (FDA) on Wednesday allowed the use of CoronaVac, the COVID-19 vaccine developed by Chinese drugmaker Sinovac Biotech, on senior citizens.

This came after the country’s vaccine experts panel’s recommendation to use the vaccine on the elderly.

READ: Vaccine expert panel OKs use of Sinovac COVID-19 vax on seniors

Article continues after this advertisement

The agencies also considered vaccine shortage and the “the growing need to protect seniors amid the increasing number of COVID-19 cases in the country.”

FEATURED STORIES

The DOH and FDA stressed, however, that vaccination of senior citizens with CoronaVac should be preceded by a thorough assessment of the individual’s health status and risk of exposure.

“After considering the recommendation of the experts and the current situation of high COVID-19 transmission and limited available vaccines, the FDA is allowing the use of Sinovac [CoronaVac] on senior citizens,” FDA Director General Eric Domingo said in a statement.

Article continues after this advertisement

“Vaccination should be preceded by an evaluation of the person’s health status and exposure risk to assure that benefits of vaccination outweigh risks,” he added.

Article continues after this advertisement

The agencies urged the public, especially senior citizens and persons with comorbidities, to register and participate in the COVID-19 vaccination program.

Article continues after this advertisement

Previously, the FDA did not prescribe CoronaVac on senior citizens, claiming that it could be used only on clinically healthy individuals aged 18 to 59 years.

Currently, the government is immunizing older people with AstraZeneca vaccines.

Article continues after this advertisement

READ: Despite EUA, FDA advises vs using Sinovac on healthcare workers, seniors due to low efficacy

CoronaVac’s efficacy rate in trials performed in Brazil, Indonesia, and Turkey ranged between 50.4 percent, 65 percent, and 91.25 percent.

abc
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Coronavac, DoH, FDA, Sinovac

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.